Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The current trial will examine the efficacy and safety of Exubera administered as a mealtime
insulin compared to lispro, when added to an existing regimen of basal insulin glargine + or
= Oral Agents (OAs). Dose titrations will be provided which should allow a large proportion
of subjects to reach target glycosylated hemoglobin (A1C) levels.